Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian Cancer
Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.
Dr. Konner Discusses PARP Inhibitors in Ovarian Cancer
Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.
Dr. Konner on Bevacizumab in Ovarian Cancer
Jason A. Konner, MD, from Memorial Sloan-Kettering Cancer Center, explains that one of the main drivers behind research into bevacizumab in ovarian cancer is to identify which patients will benefit the most from the treatment.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512